These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 25943175

  • 21. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y, Yang JF, Qi XL, Wang YQ, Wang WZ, Chen B.
    Zhonghua Yi Xue Za Zhi; 2004 Oct 17; 84(20):1686-9. PubMed ID: 15569425
    [Abstract] [Full Text] [Related]

  • 22. A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters.
    Kanjanasilp J, Sawangjit R, Phanthaisong S, Borihanthanawuth W.
    Pharmacogenomics; 2021 Jul 17; 22(10):629-640. PubMed ID: 34060344
    [Abstract] [Full Text] [Related]

  • 23. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.
    Dagenais R, Wilby KJ, Elewa H, Ensom MHH.
    Drugs R D; 2017 Sep 17; 17(3):341-361. PubMed ID: 28748348
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
    Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA.
    Pharmacogenetics; 2001 Dec 17; 11(9):803-8. PubMed ID: 11740344
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Genetic Polymorphisms of Cytochrome p450 (2C9) Enzyme in Patients with Type 2 Diabetes Mellitus in Turkmen and Fars Ethnic Groups.
    Rabiee M, Marjani A, Khajeniazi S, Mojerloo M.
    Endocr Metab Immune Disord Drug Targets; 2018 Dec 17; 18(6):653-661. PubMed ID: 30129421
    [Abstract] [Full Text] [Related]

  • 31. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
    Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K.
    Ther Drug Monit; 2014 Jun 17; 36(3):406-9. PubMed ID: 24365988
    [Abstract] [Full Text] [Related]

  • 32. Relevance of CYP2C9 Function in Valproate Therapy.
    Monostory K, Nagy A, Tóth K, Bűdi T, Kiss Á, Déri M, Csukly G.
    Curr Neuropharmacol; 2019 Jun 17; 17(1):99-106. PubMed ID: 29119932
    [Abstract] [Full Text] [Related]

  • 33. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
    López M, Dorado P, Monroy N, Alonso ME, Jung-Cook H, Machín E, Peñas-Lledó E, Llerena A.
    Drug Metabol Drug Interact; 2011 Jun 17; 26(1):5-12. PubMed ID: 21557672
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India.
    Ramasamy K, Narayan SK, Chanolean S, Chandrasekaran A.
    Neurol India; 2007 Jun 17; 55(4):408-9. PubMed ID: 18040121
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.
    Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G.
    Eur J Clin Pharmacol; 2018 Apr 17; 74(4):455-464. PubMed ID: 29273968
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.